Eyp-1901 for Age related macular degeneration

Phase-Based Progress Estimates
EyePoint Investigative Site, Melbourne, FL
Age related macular degeneration+1 More
Eyp-1901 - Drug
All Sexes
What conditions do you have?

Study Summary

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.

Eligible Conditions

  • Age related macular degeneration

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Age related macular degeneration

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Week 28 and Week 32

Baseline, Week 56
Change in best corrected visual acuity (BCVA)
Mean change in central retinal thickness on optical coherence tomography (OCT)
Week 32
Average change in best corrected visual acuity (BCVA)
Week 56
Number of rescue injections

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Age related macular degeneration

Trial Design

3 Treatment Groups

1 of 3
EYP-1901 2060 ug
1 of 3
EYP-1901 3090 ug
1 of 3
Active Control
Experimental Treatment

150 Total Participants · 3 Treatment Groups

Primary Treatment: Eyp-1901 · No Placebo Group · Phase 2

EYP-1901 2060 ug
Experimental Group · 1 Intervention: Eyp-1901 · Intervention Types: Drug
EYP-1901 3090 ug
Experimental Group · 1 Intervention: Eyp-1901 · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Aflibercept 2Mg/0.05Ml Inj,Oph · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 28 and week 32
Closest Location: EyePoint Investigative Site · Melbourne, FL
Photo of florida 1Photo of florida 2Photo of florida 3
2022First Recorded Clinical Trial
0 TrialsResearching Age related macular degeneration
1 CompletedClinical Trials

Who is running the clinical trial?

EyePoint Pharmaceuticals, Inc.Lead Sponsor
12 Previous Clinical Trials
1,552 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have previously been treated with at least two anti VEGF intravitreal injections (i.e.
You have a BCVA of 35 letters (20/200 Snellen equivalent) to 80 letters (20/25 Snellen equivalent) in the study eye at the Screening Visit and on Day 1.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.